At Cancer Care Associates, we believe in the power of cancer research and the hope it gives to millions of patients worldwide. In fact, we have more patients involved with national and pharmaceutical clinical trials than any other cancer treatment center in the central valley. Our participation in this research has improved cancer care for people in our geographic region and around the world. These clinical trials cover a broad spectrum of diagnosis and include cancer, non-cancer, prevention and symptom management studies.
Cancer Care Associates is dedicated to cancer research with ongoing clinical trials with specific departments focused solely on these studies. By participating in these clinical trials, Cancer Care Associates has privileged access to treatment options that would not otherwise be available. Implementing the proper techniques with world-renowned research institutions is another example of Cancer Care Associates committment to treatment. These leading edge therapies significantly increase treatment options for our patients, which aide in the plight against cancer. These trials not only have a direct benefit on our patients’ health, but they deliver positive results which can be shared and utilized in clinics worldwide. We take pride in our ongoing clinical trials with various research groups such as the prestigious Mayo Clinic. It is our quest to continually strive to reduce the number of cancer patients, deliver the most advanced forms of procedures and promote novel approaches to ongoing treatment.
Cancer Care Associates are members of the following research groups:
• NCCTG (North Central Cancer Treatment Group affiliate through
The Mayo Clinic)
http://ncctg.mayo.edu/
• VEDDA Oncology
https://www.iononline.com/
Cancer Care Associates are currently involved in clinical trials concerning breast cancer, colorectal cancer, head and neck cancers, lung cancer and ovarian cancer, as well as studies focusing on pain control and sleep improvement.
Cancer Care Associates Trials Open to Accrual
Breast
PACCT-1 * Oncotype RS: Randomized to hormonal tx vs hormonal tx plus chemo, for pts with ER+ and/or PR+, HER2 neg, node neg breast cancer (1.1cm-5cm lesion)
CALGB 40101Phase III randomized trial to either Cyclophosphamide and Doxorubicin(CA X4 cycles)versus Paclitaxel(4cycles) as adjuvant therapy for breast cancer in women with 0-3 postive axillary lymph nodes or high risk
NSABP B-40 A randomized phase III trial of Neoadjuvant therapy in patients with Palpable and Operable Brest Cancer evaluating the Effect on pathological complete response(pCR) of adding Capcitabine or Gem to Docetaxel when Administred before AC with or without Bev.(requires additional biopsy samples)
Colon Cancer/Rectal Cancer
NSABP R-04 A Randomized study comparing preoperative radiation therapy and capcitabine with or without oxaliplatin to preoperative radiation therapy and continous infusion 5FU with or without oxalipatin ofr patients with operable rectal cancer
Multiple Myeloma
UPFRONT/I-07-016 A randomized trial of 3 treatment regimens for patients not previously treated and not considered candidates for high dose chemo/stem cell transplant. Regimens Include Velcade with dexamethasone or Velcade with Thalidomide and dexamethasone or Velcade with melphalan and prednisone.
Lymphoma
RATE Open-Label study of Rituximab faster infusion time for previously untreated padiffuse large B-cell or Follicular Non-Hodgkins lymphoma.
Prostate
S0421 A phase III study of Docetaxel and Atrasentan VS Docetaxel and placebo for patients with Advance Hormone Refractory Prostate cancer.
Brain
N0776 A trial of Avastin in combination with Nexavar in patients with recurrent glioblastoma multiforme.
Renal
VEG108844 A randomized, open label study to compare pazopanib to sunitinib in patients with advanced renal cell cancer who have not previously received prior systemic therapy for advanced or metastatic renal cell cancer.
REGISTRY TRIALS
Breast
VIRGO Locally recurrent or metast. Breast Ca. receipt of 1st. systemic cytotoxic chemo and/or targeted therapy among those with Her-2 normal diseasea or 1st hormone TX among those w/HR+disease for TX of locally recurrent or mets. Disease no greater than 1 month prior to enrollment
MDS
MORE REGISTRY Iron overloaded, lower risk Myelodysplastic patients registry.
HEAD AND NECK CANCER
LORHAN Prospective, Longitudinal, Multi-Center Descriptive Registry of Patients Receiving Therapy other than Surgical Resection Alone for Newly Diagnosed Head and Neck Carcinoma.
